Advertisement
Advertisement

IBIO

IBIO logo

iBio, Inc. Common Stock

2.23
USD
Sponsored
-0.06
-2.83%
Feb 03, 15:59 UTC -5
Closed
exchange

After-Market

2.26

+0.02
+1.07%

IBIO Earnings Reports

Positive Surprise Ratio

IBIO beat 7 of 17 last estimates.

41%

Next Report

Next Week
Date of Next Report
Feb 09, 2026
Estimate for Q2 26 (Revenue/ EPS)
$34.00K
/
-$0.10
Implied change from Q1 26 (Revenue/ EPS)
-66.00%
/
-9.09%
Implied change from Q2 25 (Revenue/ EPS)
-83.00%
/
-79.17%

iBio, Inc. Common Stock earnings per share and revenue

On Nov 12, 2025, IBIO reported earnings of -0.11 USD per share (EPS) for Q1 26, missing the estimate of -0.10 USD, resulting in a -5.16% surprise. Revenue reached 100.00 thousand, compared to an expected 25.50 thousand, with a 292.16% difference. The market reacted with a -8.00% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 6 analysts forecast an EPS of -0.10 USD, with revenue projected to reach 34.00 thousand USD, implying an decrease of -9.09% EPS, and decrease of -66.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
logo
Amgen Inc
Report Date
Feb 03, 2026 For Q4 25
Estimate
$4.82
Actual
$5.29
Surprise
+9.56%
logo
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
logo
Twist Bioscience Corporation Common Stock
Report Date
Feb 02, 2026 For Q1 26
Estimate
-$0.43
Actual
-$0.50
Surprise
-14.00%
logo
AYTU BioPharma, Inc. Common Stock
Report Date
Feb 03, 2026 For Q2 26
Estimate
-$0.61
Actual
-$1.05
Surprise
-71.57%
FAQ
For Q1 2026, iBio, Inc. Common Stock reported EPS of -$0.11, missing estimates by -5.16%, and revenue of $100.00K, 292.16% above expectations.
The stock price moved down -8%, changed from $1.25 before the earnings release to $1.15 the day after.
The next earning report is scheduled for Feb 09, 2026.
Based on 6 analysts, iBio, Inc. Common Stock is expected to report EPS of -$0.10 and revenue of $34.00K for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement